Investigating a new approach to prevent blood vessel growth in pulmonary arterial hypertension
Targeting FAK-NEDD9 protein-protein interaction to prevent focal adhesion assembly and vascular proliferation in pulmonary arterial hypertension
This study is looking at a new treatment for pulmonary arterial hypertension (PAH) that aims to stop harmful changes in the lungs by blocking the interaction between two proteins, which could help PAH patients without the side effects of current cancer therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10857303 on NIH RePORTER |
What this research studies
This research focuses on pulmonary arterial hypertension (PAH), a serious condition that leads to the proliferation of cells in the lungs and thickening of blood vessel walls. The team aims to develop a targeted therapy that inhibits the assembly of focal adhesions, which are crucial for cell growth and tissue remodeling. By specifically blocking the interaction between two proteins, FAK and NEDD9, the researchers hope to reduce harmful vascular changes associated with PAH. This approach is designed to minimize side effects that current cancer treatments may cause in PAH patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension who are experiencing significant symptoms.
Not a fit: Patients with other forms of pulmonary hypertension or those without a confirmed diagnosis of PAH may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that effectively manages pulmonary arterial hypertension and improves patient outcomes.
How similar studies have performed: While the approach of targeting the FAK-NEDD9 interaction is novel, previous research has shown that inhibiting similar pathways can be effective in managing vascular diseases.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Maron, Bradley — University of Maryland Baltimore
- Study coordinator: Maron, Bradley
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.